Choroidal neovascularization associated with extensive macular atrophy and pseudodrusen.
OBJECTIVE
To describe a case of extensive macular atrophy and pseudodrusen complicated by bilateral choroidal neovascularization (CNV).


METHODS
A 53-year-old woman showed extensive macular atrophy at the posterior pole associated with disciform scar in the right eye and fibrotic juxtafoveal CNV in the left eye.


RESULTS
The patient underwent a complete ophthalmological examination including fundus autofluorescence, fluorescein angiography, and spectral-domain optical coherence tomography, showing a disciform scar at the posterior pole of the right eye and an extensive macular atrophy associated with a fibrotic juxtafoveal CNV. The patient was previously treated with four and seven intravitreal bevacizumab injections, respectively, in the right eye and in the left eye. Molecular analyses of the ABCA4 gene revealed the variant c.1268A<G.


CONCLUSIONS
Although the natural course of extensive macular atrophy and pseudodrusen usually leads to the enlargement of the macular atrophy, extensive macular atrophy and pseudodrusen can also complicate with bilateral CNV. Intravitreal bevacizumab can help stop the CNV activity.
*MD †MD, PhD Department of Ophthalmology, University Vita-Salute, Ospedale San Raffaele, Milan, Italy (both authors).
Maurizio Battaglia
MB
Parodi
Giuseppe
G
Querques
D018528:ATP-Binding Cassette Transporters / Q000235:genetics; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D003317:Corneal Dystrophies, Hereditary / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D058449:Intravitreal Injections; D008875:Middle Aged; D015593:Retinal Drusen / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
C056475:ABCA4 protein, human; D018528:ATP-Binding Cassette Transporters; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab